Biological Products, (No Diagnostic Substances) · DE · CIK 1764013
Developing IMVT-1402 to treat autoimmune diseases by inhibiting FcRn and reducing pathogenic IgG antibodies
Comparable business profile · signals at a glance
In the 90 days to Mar 18, 2026: 3 sold $536K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 18, 2026 | Van Tuyl ChristopherChief Legal Officer | Sell | 2,877 | $24.97 | $72K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 1,437 | $26.98 | $39K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 942 | $28.90 | $27K |
| Feb 25, 2026 | Gloria MelanieChief Operating Officer | Sell | 859 | $28.16 | $24K |
| Jan 21, 2026 | Stout Jay SChief Technology Officer | Sell | 1,977 | $26.03 | $51K |
| Jan 7, 2026 | Stout Jay SChief Technology Officer | Sell | 1,148 | $26.51 | $30K |
| Jan 7, 2026 | Stout Jay SChief Technology Officer | Sell | 55 | $26.92 | $1K |
| Dec 18, 2025 | Van Tuyl ChristopherChief Legal Officer | Sell | 8,529 | $26.78 | $228K |
| Dec 18, 2025 | Van Tuyl ChristopherChief Legal Officer | Sell | 2,284 | $27.38 | $63K |
| Dec 12, 2025 | Roivant Sciences Ltd.Director,TenPercentOwner | Buy | 16,666,666 | $21.00 | $350.0M |
| Dec 1, 2025 | Fromkin Andrew J.Director | Sell | 19,351 | $23.14 | $448K |
| Dec 1, 2025 | Hughes Douglas J.Director | Sell | 13,091 | $23.14 | $303K |
| Dec 1, 2025 | Fromkin Andrew J.Director | Sell | 2,898 | $23.95 | $69K |
| Dec 1, 2025 | Hughes Douglas J.Director | Sell | 1,909 | $23.96 | $46K |
| Nov 20, 2025 | Gloria MelanieChief Operating Officer | Sell | 10,251 | $23.54 | $241K |
| Nov 20, 2025 | Gloria MelanieChief Operating Officer | Sell | 2,375 | $23.97 | $57K |
| Oct 22, 2025 | Geffner MichaelChief Medical Officer | Sell | 2,595 | $19.03 | $49K |
| Oct 22, 2025 | Stout Jay SChief Technology Officer | Sell | 2,520 | $19.03 | $48K |
| Oct 8, 2025 | Stout Jay SChief Technology Officer | Sell | 1,585 | $16.30 | $26K |
| Oct 8, 2025 | Geffner MichaelChief Medical Officer | Sell | 1,272 | $16.30 | $21K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Reputable outlets only (Reuters, WSJ, CNBC, Barron's, and peers). More on Google News ↗